Clinical trials confirmed no effect on serum IGF-1 levels, no negative effect on carbohydrate metabolism, and no anti-AOD-9604 antibodies detected in any participants
Disposition : Structure: Acylated peptide with a fatty diacid moiety extends half-life via albumin binding Half-life: ~6 days supports once-weekly dosing Administration: Subcutaneous injection Clinical Data Highlights : Weight Loss: Up to 24.2% body weight reduction in phase 2 trials, highest recorded among incretin-based therapies Glycemic Control: HbA1c reductions of 2.02.5% in type 2 diabetes patients Lipid Profile: Significant drops in triglycerides, LDL-C, and liver fat content Insulin Sensitivity: Improved HOMA-IR and fasting insulin levels Energy Expenditure: Increased basal metabolic rate and fat oxidation via glucagon receptor activation For a full breakdown of Retatrutide clinical trials and results you can click the link
Then label the vial and the study log the same way every time
GHK-Cu: The Rejuvenating Power of Peptide Therapy What is GHK-Cu
It means that as a standalone oral therapy at the tested doses, it did not produce the magnitude of weight loss that pharmaceutical companies require for commercial viability
This was confirmed across multiple studies measuring serum IGF-1 at baseline and throughout treatment